DMAAR Drugs Made in America Acquisition Corp.
Fundamentals / CIK 0002028614 / USDDrugs Made in America Acquisition Corp. reported $147.5M in total assets and net income of $5.16M through December 31, 2025 from SEC EDGAR filings.
Audited annual (10-K / 20-F) and quarterly (10-Q) statements parsed directly from SEC EDGAR CompanyFacts. Open DMAAR in the Convexity terminal for live prices, valuation multiples, transcripts, and insider flow.
-
Revenue FY 2025-- Dec 31, 2025
-
Operating Income FY 2025-$2.47M Operating profit
-
Net Income FY 2025$5.16M GAAP bottom line
-
Diluted EPS FY 2025-- Split-adjusted
-
Free Cash Flow FY 2025-- Operating CF less CapEx
-
Cash & ST Investments Sep 30, 2026$17K Total debt: --
Financial statements and ratios
Reported in USD. Per-share figures and share counts are adjusted for stock splits from SEC filings.
Income Statement (Annual) · Reported in USD · Newest filing period first.
| Income Statement | Dec 31 |
|---|---|
| Operating Income | -$2.82M |
| Interest Income | $8.76M |
| Net Income | $5.94M |
Income Statement (Quarterly) · Reported in USD · Newest filing period first.
| Income Statement | 2026-09-30 | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-09-30 |
|---|---|---|---|---|---|---|---|---|
| Operating Income | -$96K | -$137K | -$143K | -$2.09M | -$264K | -$132K | -$331K | -$145K |
| Interest Income | $1.34M | $1.86M | $2.11M | $2.30M | $2.45M | $2.42M | $1.59M | -- |
| Net Income | $1.24M | $1.73M | $1.97M | $213K | $2.18M | $2.29M | $1.25M | -$145K |
Balance Sheet (Annual) · Reported in USD · Newest filing period first.
| Balance Sheet | Dec 31 | Dec 31 |
|---|---|---|
| Cash & Cash Equivalents | $6.1K | $1.4K |
| Cash & Short-Term Investments | $6.1K | $1.4K |
| Total Current Assets | $12K | $5.0K |
| Total Non-Current Assets | $239.9M | $546K |
| Total Assets | $239.9M | $551K |
| Total Current Liabilities | $376K | $796K |
| Deferred Revenue (Non-Current) | $6.90M | -- |
| Total Non-Current Liabilities | $6.90M | $0 |
| Total Liabilities | $7.28M | $796K |
| Common Stock | $1.1K | $986 |
| Retained Earnings | -$7.27M | -$280K |
| Total Stockholders' Equity | -$7.26M | -$245K |
| Total Equity | -$7.26M | -$245K |
Balance Sheet (Quarterly) · Reported in USD · Newest filing period first.
| Balance Sheet | 2026-09-30 | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 |
|---|---|---|---|---|---|---|---|---|
| Cash & Cash Equivalents | $17K | $20K | $15K | $6.1K | $717 | $822 | $923 | $1.4K |
| Cash & Short-Term Investments | $17K | $20K | $15K | $6.1K | $717 | $822 | $923 | $1.4K |
| Total Current Assets | $49K | $69K | $15K | $12K | $28K | $50K | $71K | $5.0K |
| Total Non-Current Assets | $147.4M | $146.8M | $242.0M | $239.9M | $237.6M | $235.2M | $232.7M | $546K |
| Total Assets | $147.5M | $146.9M | $242.0M | $239.9M | $237.6M | $235.2M | $232.8M | $551K |
| Total Current Liabilities | $2.26M | $2.94M | $492K | $376K | $457K | $301K | $347K | $796K |
| Deferred Revenue (Non-Current) | -- | -- | -- | $6.90M | -- | -- | -- | -- |
| Total Non-Current Liabilities | $6.19M | $6.19M | $6.90M | $6.90M | $6.90M | $6.90M | $6.90M | $0 |
| Total Liabilities | $8.45M | $9.14M | $7.39M | $7.28M | $7.36M | $7.20M | $7.25M | $796K |
| Common Stock | $1.1K | $1.1K | $1.1K | $1.1K | $1.1K | $1.1K | $1.1K | $986 |
| Retained Earnings | -$8.40M | -$7.41M | -$7.38M | -$7.27M | -$6.72M | -$6.46M | -$6.33M | -$280K |
| Total Stockholders' Equity | -$8.40M | -$7.41M | -$7.38M | -$7.26M | -$7.33M | -$7.15M | -$7.18M | -$245K |
| Total Equity | -$8.40M | -$7.41M | -$7.38M | -$7.26M | -$7.33M | -$7.15M | -$7.18M | -$245K |
Cash Flow Statement (Annual) · Reported in USD · Newest filing period first.
| Cash Flow Statement | Dec 31 |
|---|---|
| Net Income | $5.94M |
| Operating Cash Flow | -$539K |
| Investing Cash Flow | -$231.2M |
| Financing Cash Flow | $231.7M |
| Net Change in Cash | $4.8K |
Cash Flow Statement (Quarterly) · Reported in USD · Newest filing period first.
| Cash Flow Statement | 2026-09-30 | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-09-30 |
|---|---|---|---|---|---|---|---|---|
| Net Income | $1.24M | $1.73M | $1.97M | $213K | $2.18M | $2.29M | $1.25M | -$145K |
| Operating Cash Flow | -$78K | -$245K | -$91K | -$125K | -$56K | -$107K | -$251K | -- |
| Investing Cash Flow | -- | -- | -- | $0 | $0 | $0 | -$231.2M | -- |
| Financing Cash Flow | $975K | -$98.46M | $100K | $131K | $56K | $107K | $231.4M | -- |
| Net Change in Cash | -$3.3K | $5.4K | $8.8K | $5.4K | -$105 | -$101 | -$428 | -- |
Margins, returns, leverage, liquidity, and year-over-year growth computed directly from SEC EDGAR statement levels. Multi-year figures show cumulative per-share growth.
| Ratios & Growth | Dec 31 |
|---|---|
| Return on Assets (ROA) | 2.5% |
| Current Ratio | 0.03x |
| Quick Ratio | 0.02x |
Quarterly margins, ROE, and ROA use trailing-twelve-month (TTM) flows summed across four contiguous quarters. Growth rates are true year-over-year comparisons against the same quarter a year earlier.
| Ratios & Growth | 2026-09-30 | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-09-30 |
|---|---|---|---|---|---|---|---|---|
| Return on Assets (ROA) | 3.5% | 4.1% | 2.8% | 2.5% | -- | -- | -- | -- |
| Current Ratio | 0.02x | 0.02x | 0.03x | 0.03x | 0.06x | 0.16x | 0.20x | -- |
| Quick Ratio | 0.01x | 0.01x | 0.03x | 0.02x | 0.00x | 0.00x | 0.00x | -- |
| Net Income Growth (YoY) | -43.0% | -24.5% | +57.1% | -- | -- | -- | -- | -- |